A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D.
A Randomized, Open-Label Study to Assess Efficacy of Weekly Assumption of Cholecalciferol versus Calcifediol in Older Patients with Hypovitaminosis D.
复制标题
一项随机开放研究，评估每周服用胆钙素与钙化二醇对老年维生素D缺乏症患者的疗效。
DOI：
10.3390/geriatrics7010013
复制
发表时间：
2022-01-07
期刊：
影响因子：
--
通讯作者：
Monzani F
中科院分区：
文献类型：
--
作者：
Okoye C;Calsolaro V;Niccolai F;Calabrese AM;Franchi R;Rogani S;Coppini G;Morelli V;Caraccio N;Monzani F
这项单中心、开放标签、随机对照研究的目的是评估胆钙化醇和骨化二醇中哪种维生素 D 制剂对于治疗老年人维生素 D 缺乏症最有效。入院时记录人口统计学特征、临床病史和综合老年评估。从入院时到出院后三个月，符合条件的患者被随机分配同等维生素 D 补充剂，即胆骨化醇或骨化二醇。在 140 名老年患者中（平均年龄 83 ± 6.6 岁，57.8% 为女性），69 名患者接受了胆钙化醇治疗，71 名患者接受了骨化二醇治疗。入组时发现接受胆骨化醇治疗的患者的 25-羟基维生素 D3（25OH-维生素 D3）平均血浆值为 16.8 ± 9.9 ng/mL，而接受骨化二醇治疗的患者为 18.8 ± 13.3 ng/mL（p = 0.31）。在三个月的随访中，接受骨化二醇治疗的患者的 25OH-维生素 D3 平均浓度显着高于接受胆骨化醇治疗的患者（分别为 30.7 ± 8.4 和 45.4 ± 9.8 ng/mL；p < 0.001）。补充胆钙化醇或骨化二醇可以有效地使患有维生素 D 缺乏症的老年患者达到 25OH-维生素 D3 的最佳循环值。然而，补充骨化二醇导致 25OH-维生素 D3 的平均循环值显着高于（超过 50%）比胆钙化醇获得的值。
The aim of this single-center, open-label, randomized controlled study was to evaluate which formulation of vitamin D—between cholecalciferol and calcifediol—is most effective in the treatment of hypovitaminosis D in older adults. Demographic characteristics, clinical history, and comprehensive geriatric assessment were recorded at admission. Eligible patients were randomly assigned an equivalent vitamin D supplement, either with cholecalciferol or calcifediol, from the time of hospital admission to three months after discharge. Among the 140 older patients included (mean age 83 ± 6.6 years, 57.8% females), 69 received cholecalciferol and 71 received calcifediol. The mean plasma values of 25-hydroxyvitamin D3 (25OH-vitamin D3) found at the time of enrollment were 16.8 ± 9.9 ng/mL in patients receiving cholecalciferol and 18.8 ± 13.3 ng/mL in those treated with calcifediol (p = 0.31). At the three month follow-up, the mean concentration of 25OH-vitamin D3 was significantly higher in patients treated with calcifediol than in those receiving cholecalciferol (30.7 ± 8.4 vs. 45.4 ± 9.8 ng/mL, respectively; p < 0.001). Supplementation with either cholecalciferol or calcifediol effectively results in reaching the optimal circulating values of 25OH-vitamin D3 in older patients suffering from hypovitaminosis D. However, supplementation with calcifediol led to average circulating values of 25OH-vitamin D3 that were significantly higher (over 50%) than those obtained with cholecalciferol.